275 related articles for article (PubMed ID: 22872109)
21. Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation.
DeGraba TJ
Stroke; 2004 Nov; 35(11 Suppl 1):2712-9. PubMed ID: 15472106
[TBL] [Abstract][Full Text] [Related]
22. Do we need to consider inflammatory markers when we treat atherosclerotic disease?
Athyros VG; Kakafika AI; Karagiannis A; Mikhailidis DP
Atherosclerosis; 2008 Sep; 200(1):1-12. PubMed ID: 18420211
[TBL] [Abstract][Full Text] [Related]
23. Advances in mechanisms, imaging and management of the unstable plaque.
Niccoli G; Liuzzo G; Montone RA; Crea F
Atherosclerosis; 2014 Apr; 233(2):467-477. PubMed ID: 24530781
[TBL] [Abstract][Full Text] [Related]
24. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.
Stoll G; Bendszus M
Stroke; 2006 Jul; 37(7):1923-32. PubMed ID: 16741184
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-17 and acute coronary syndrome.
Su SA; Ma H; Shen L; Xiang MX; Wang JA
J Zhejiang Univ Sci B; 2013 Aug; 14(8):664-9. PubMed ID: 23897784
[TBL] [Abstract][Full Text] [Related]
26. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC
Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472
[TBL] [Abstract][Full Text] [Related]
27. Effects of statins on plaque rupture assessed by optical coherence tomography in patients presenting with acute coronary syndromes: insights from the optical coherence tomography (OCT)-FORMIDABLE registry.
Gili S; Iannaccone M; Colombo F; Montefusco A; Amabile N; Calcagno S; Capodanno D; Scalone G; Rognoni A; Omedè P; Ugo F; Cavallo E; Mancone M; Mangiameli A; Boccuzzi G; Hiansen J; Motreff P; Toutouzas K; Garbo R; Sardella G; Tamburino C; D'Amico M; Moretti C; Templin C; Gaita F; Souteyrand G; Niccoli G; D'Ascenzo F
Eur Heart J Cardiovasc Imaging; 2018 May; 19(5):524-531. PubMed ID: 28605473
[TBL] [Abstract][Full Text] [Related]
28. Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
Monroe VS; Kerensky RA; Rivera E; Smith KM; Pepine CJ
J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):23S-30S. PubMed ID: 12644337
[TBL] [Abstract][Full Text] [Related]
29. The role of inflammation and allergy in acute coronary syndromes.
Ozben B; Erdogan O
Inflamm Allergy Drug Targets; 2008 Sep; 7(3):136-44. PubMed ID: 18782020
[TBL] [Abstract][Full Text] [Related]
30. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture.
Boyle JJ
Curr Vasc Pharmacol; 2005 Jan; 3(1):63-8. PubMed ID: 15638783
[TBL] [Abstract][Full Text] [Related]
31. NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins.
Altaf A; Qu P; Zhao Y; Wang H; Lou D; Niu N
Coron Artery Dis; 2015 Aug; 26(5):409-21. PubMed ID: 25946654
[TBL] [Abstract][Full Text] [Related]
32. Pathophysiology and mechanisms of Acute Coronary Syndromes: atherothrombosis, immune-inflammation, and beyond.
Cimmino G; Di Serafino L; Cirillo P
Expert Rev Cardiovasc Ther; 2022 May; 20(5):351-362. PubMed ID: 35510629
[TBL] [Abstract][Full Text] [Related]
33. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rosenson RS
Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
[TBL] [Abstract][Full Text] [Related]
34. Innate immune system cells in atherosclerosis.
Chávez-Sánchez L; Espinosa-Luna JE; Chávez-Rueda K; Legorreta-Haquet MV; Montoya-Díaz E; Blanco-Favela F
Arch Med Res; 2014 Jan; 45(1):1-14. PubMed ID: 24326322
[TBL] [Abstract][Full Text] [Related]
35. Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease.
Maranhão RC; Leite AC
Curr Pharm Des; 2015; 21(9):1196-204. PubMed ID: 25312729
[TBL] [Abstract][Full Text] [Related]
36. Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis - a review of the experimental evidence.
Björkbacka H; Fredrikson GN; Nilsson J
Atherosclerosis; 2013 Mar; 227(1):9-17. PubMed ID: 23177975
[TBL] [Abstract][Full Text] [Related]
37. Atherothrombosis in Acute Coronary Syndromes-From Mechanistic Insights to Targeted Therapies.
Khandkar C; Madhavan MV; Weaver JC; Celermajer DS; Karimi Galougahi K
Cells; 2021 Apr; 10(4):. PubMed ID: 33920201
[TBL] [Abstract][Full Text] [Related]
38. In vivo near infrared fluorescence (NIRF) intravascular molecular imaging of inflammatory plaque, a multimodal approach to imaging of atherosclerosis.
Calfon MA; Rosenthal A; Mallas G; Mauskapf A; Nudelman RN; Ntziachristos V; Jaffer FA
J Vis Exp; 2011 Aug; (54):. PubMed ID: 21847078
[TBL] [Abstract][Full Text] [Related]
39. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD.
Müller KA; Chatterjee M; Rath D; Geisler T
Thromb Haemost; 2015 Aug; 114(3):498-518. PubMed ID: 26224127
[TBL] [Abstract][Full Text] [Related]
40. What have we learned about plaque rupture in acute coronary syndromes?
Choi SY; Mintz GS
Curr Cardiol Rep; 2010 Jul; 12(4):338-43. PubMed ID: 20425160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
